Program
Please note that this meeting will take place as an in-person event in San Diego and will not live-stream content for virtual participation. The meeting content will be recorded and made available as an on-demand program after the conference.
All presentations are scheduled to be live, in-person presentations at the date and time specified below unless noted otherwise. Program in progress.
Thursday, October 19, 2023
Friday, October 20, 2023
- Plenary Session 1: Models
- Plenary Session 2: Inflammation, the Microenvironment, and Metabolism
- Plenary Session 3: Panel Discussion on Biomarkers
Saturday, October 21, 2023
- Plenary Session 4: Functional Interpretation of “Omics”
- Plenary Session 5: Heterogeneity
- Plenary Session 6: Personalized Risk and Prevention
Sunday, October 22, 2023
- Plenary Session 7: Mechanisms of Treatment Resistance
- Plenary Session 8: Future Therapies & Immuno-Oncology
Thursday, October 19, 2023
WELCOME AND OPENING KEYNOTE
6-7:15 P.M.
Welcome from Cochairs
Targeting PI3K for treating breast cancer
Lewis C. Cantley, Dana-Farber Cancer Institute, Boston, Massachusetts
OPENING RECEPTION
7:15-9 P.M.
Friday, October 20, 2023
CONTINENTAL BREAKFAST
7-8 A.M.
PLENARY SESSION 1: models
8-10:15 A.M.
Breast cancer evolution
Joan S. Brugge, Harvard Medical School, Boston, Massachusetts
Patient-derived models of breast cancer for discovery science and precision medicine
Alana L. Welm, University of Utah Huntsman Cancer Institute, Salt Lake City, Utah
Title to be announced
Jos Jonkers, Netherlands Cancer Institute, Amsterdam, Netherlands
Short talks from proffered abstracts
BREAK
10:15-10:30 A.M.
PLENARY SESSION 2: Inflammation, the Microenvironment, and Metabolism
10:30 A.M.-12:45 P.M.
Title to be announced
Robert Weinberg, MIT Whitehead Institute for Biomedical Research, Cambridge, Massachusetts
Title to be announced
Pepper Schedin, Oregon Health and Science University, Portland, Oregon
Highly multiplexed imaging for personalised breast immuno-oncology
H. Raza Ali, CRUK Cambridge Institute/University of Cambridge, Cambridge, United Kingdom
Short talks from proffered abstracts
LUNCH
12:45-2:30 P.M.
PLENARY SESSION 3: Panel Discussion on Biomarkers
2:30-4:30 P.M.
Quantitative biomarkers for breast cancer patients
Charles M. Perou, University of North Carolina, Chapel Hill, North Carolina
Title to be announced
Gordon B. Mills, Oregon Health and Science University, Portland, Oregon
Optimal therapy outcome for high-risk breast cancer patients by response predictive subtypes
Laura J. van ‘t Veer, University of California San Francisco, San Francisco, California
Poster Session A/Reception
5-7 P.M.
Saturday, October 21, 2023
CONTINENTAL BREAKFAST
7-8 A.M.
PLENARY SESSION 4: Functional interpretation of “Omics”
8-10:15 A.M.
Using a cancer dependency map
William C. Hahn, Dana-Farber Cancer Institute, Boston, Massachusetts
Title to be announced
Christina Curtis, Stanford University, Stanford, California
Additional speaker to be announced
Short talks from proffered abstracts
BREAK
10:15-10:30 A.M.
PLENARY SESSION 5: Heterogeneity
SESSION CHAIR: Jane E. Visvader, Walter & Eliza Hall Institute of Medical Research, Parkville, Australia
10:15 A.M.-12:15 P.M.
Decoding normal breast tissues and premalignant cancer with single cell genomics
Nicholas E. Navin, The University of Texas MD Anderson Cancer Center, Houston, Texas
Title to be announced
Samuel Aparicio, BC Cancer Research Centre, Vancouver, BC, Canada
Creation and preliminary analyses of a full spectrum of breast cancers initiated de novo from normal human mammary cells
Connie J. Eaves, BC Cancer Research Institute, Vancouver, BC, Canada
Short talks from proffered abstracts
LUNCH ON OWN
12:45-2:45 P.M.
PLENARY SESSION 6: personalized risk and prevention
2:45-5 P.M.
Harnessing endocrine control mechanism for breast cancer prevention
Cathrin Briskin, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland
Genetic susceptibility to breast cancer: Recent advances and application to personalised prevention
Douglas Easton, University of Cambridge, Cambridge, United Kingdom
Title to be announced
Susan M. Domchek, University of Pennsylvania, Philadelphia, Pennsylvania
Short talks from proffered abstracts
POSTER SESSION B / RECEPTION
5-7 P.M.
Sunday, October 22, 2023
CONTINENTAL BREAKFAST
7-8 A.M.
PLENARY SESSION 7: mechanisms of treatment resistance
SESSION CHAIR: Jason S. Carroll, Cancer Research UK Cambridge Research Institute, Cambridge, United Kingdom
8-10 A.M.
Redefining luminal breast cancer subtypes
Wilbert Zwart, Netherlands Cancer Institute, Amsterdam, Netherlands
Mechanisms of resistance to HER2 tragedy therapies
Rachel Schiff, Baylor College of Medicine, Houston, Texas
Title to be announced
Carlos L. Arteaga, UT Southwestern Medical Center, Dallas, Texas
Short talks from proffered abstracts
BREAK
10-10:20 A.M.
PLENARY SESSION 8: future therapies and immuno-oncology
SESSION CHAIR: Pepper Schedin, Oregon Health and Science University, Portland, Oregon
10:20 A.M.-12:20 P.M.
Title to be announced
Jenny C. Chang, Houston Methodist Hospital Cancer Center, Houston, Texas
Microbiota and breast cancer: the power of small things
Dipali Sharma, Johns Hopkins University School of Medicine, Baltimore, Maryland
Exploring breast cancer vulnerabilities through apoptotic pathways
Geoffrey J. Lindeman, Walter & Eliza Hall Institute of Medical Research, Parkville, Australia
Short talks from proffered abstracts
CLOSING keynote
12:15-1 P.M.
Breast cancer: Enormous progress, ongoing challenges
Judy E. Garber, Dana-Farber Cancer Institute, Boston, Massachusetts